Lentinan‐Enhanced Mn 3 O 4 Nanoparticles for Neuroinflammation Relief and Parkinson's Disease Treatment
Small · 2026-06 · 22 (32)
DOI: 10.1002/smll.202509328 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 22.04.2026. Verfasst von Ruixue Wei und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Parkinson Disease, Nanoparticles, Oxides, Manganese Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Tackle Key Problems in Science and Technology Project of Henan Province, Key R&D and Promotion Special Projects of Henan Province.
Abstract (Originalsprache)
Neuroinflammation plays an irreplaceable part in the pathogenesis and progression of Parkinson's disease (PD). While anti‐inflammatory nanomedicine offers new hope for PD treatment, the nano‐biological effects that govern their therapeutic outcomes remain largely unexplored. Herein, after investigating the mechanism of action of lentinan (LNT) on PD by network pharmacology, we report LNT and Mn 3 O 4 integrated nanosystems (Mn 3 O 4 @LNT) as anti‐neuroinflammatory agents for PD treatment. Proteomics analyses found that there are significant differences in protein corona composition between Mn 3 O 4 and Mn 3 O 4 @LNT, and the protein coronas in Mn 3 O 4 @LNT are beneficial for BBB traversing and brian accumulation. In vivo and in vitro studies have shown that Mn 3 O 4 @LNT effectively alleviates the behavioral and pathological symptoms of PD by eliminating reactive oxygen species and reducing neuroinflammation. Transcriptomics further revealed the vital part of the phenotypic transformation of microglia and inflammatory response in the action of Mn 3 O 4 @LNT on the PD model. In summary, our study highlights the clinical application prospects of Mn 3 O 4 @LNT by benefiting the BBB traversing and promoting neuroinflammation mitigation in PD models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Neurology, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Zhengzhou Key Laboratory of Bio-Nanomedicine for Neurodegenerative Diseases, Zhengzhou, China.
- School of Life Sciences, Zhengzhou University, Zhengzhou, China.
- Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, P. R. China.
- Research Institute of Nephrology, Zhengzhou University, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China.
ORCID-Profile: Nan Li
Förderung
- National Natural Science Foundation of China
- Tackle Key Problems in Science and Technology Project of Henan Province
- Key R&D and Promotion Special Projects of Henan Province
- Excellent Young Scientists Fund Program of the Natural Science Foundation of Henan Province
- Young and Middle-aged Innovation Talents of Health Science and Technology Project in Henan Province
Zitieren
APA
Wei, R., Zhang, X., Zhang, J., Chang, Z., Wang, K., Chen, J., Feng, Q., & Li, N. (2026). Lentinan‐Enhanced Mn 3 O 4 Nanoparticles for Neuroinflammation Relief and Parkinson's Disease Treatment. Small, 22(32). https://doi.org/10.1002/smll.202509328
Vancouver
Wei R, Zhang X, Zhang J, Chang Z, Wang K, Chen J, et al. Lentinan‐Enhanced Mn 3 O 4 Nanoparticles for Neuroinflammation Relief and Parkinson's Disease Treatment. Small. 2026;22(32). doi:10.1002/smll.202509328
BibTeX
@article{Wei2026,
author = {Wei, Ruixue and Zhang, Xu and Zhang, Jiangkuan and Chang, Zhaohui and Wang, Ke and Chen, Junyang and Feng, Qi and Li, Nan},
title = {Lentinan‐Enhanced Mn 3 O 4 Nanoparticles for Neuroinflammation Relief and Parkinson's Disease Treatment},
journal = {Small},
year = {2026},
volume = {22},
number = {32},
doi = {10.1002/smll.202509328}
}
EUVIMED